SI3735226T1 - Injekcijski sestavki triterpenoidnih antimikotikov, vkapsuliranih v liposomih - Google Patents

Injekcijski sestavki triterpenoidnih antimikotikov, vkapsuliranih v liposomih

Info

Publication number
SI3735226T1
SI3735226T1 SI201830746T SI201830746T SI3735226T1 SI 3735226 T1 SI3735226 T1 SI 3735226T1 SI 201830746 T SI201830746 T SI 201830746T SI 201830746 T SI201830746 T SI 201830746T SI 3735226 T1 SI3735226 T1 SI 3735226T1
Authority
SI
Slovenia
Prior art keywords
triterpenoid
antifungals
liposome
encapsulated
injectable formulations
Prior art date
Application number
SI201830746T
Other languages
English (en)
Slovenian (sl)
Inventor
Rajeshwar Motheram
Original Assignee
Scynexis, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scynexis, Inc. filed Critical Scynexis, Inc.
Publication of SI3735226T1 publication Critical patent/SI3735226T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
SI201830746T 2018-01-02 2018-12-21 Injekcijski sestavki triterpenoidnih antimikotikov, vkapsuliranih v liposomih SI3735226T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862612893P 2018-01-02 2018-01-02
PCT/US2018/067216 WO2019135954A1 (en) 2018-01-02 2018-12-21 Injectable compositions of triterpenoid antifungals encapsulated in liposomes
EP18834263.8A EP3735226B1 (en) 2018-01-02 2018-12-21 Injectable compositions of triterpenoid antifungals encapsulated in liposomes

Publications (1)

Publication Number Publication Date
SI3735226T1 true SI3735226T1 (sl) 2022-11-30

Family

ID=65024141

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201830746T SI3735226T1 (sl) 2018-01-02 2018-12-21 Injekcijski sestavki triterpenoidnih antimikotikov, vkapsuliranih v liposomih

Country Status (27)

Country Link
US (3) US20200338002A1 (cg-RX-API-DMAC7.html)
EP (2) EP4137123A1 (cg-RX-API-DMAC7.html)
JP (3) JP7378401B2 (cg-RX-API-DMAC7.html)
KR (1) KR102694692B1 (cg-RX-API-DMAC7.html)
CN (2) CN115998684A (cg-RX-API-DMAC7.html)
AU (1) AU2018399599B2 (cg-RX-API-DMAC7.html)
CA (1) CA3087176A1 (cg-RX-API-DMAC7.html)
DK (1) DK3735226T3 (cg-RX-API-DMAC7.html)
EA (1) EA202091626A1 (cg-RX-API-DMAC7.html)
ES (1) ES2927051T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20221295T1 (cg-RX-API-DMAC7.html)
HU (1) HUE060400T2 (cg-RX-API-DMAC7.html)
IL (2) IL275758B2 (cg-RX-API-DMAC7.html)
LT (1) LT3735226T (cg-RX-API-DMAC7.html)
MA (1) MA51514A (cg-RX-API-DMAC7.html)
MD (1) MD3735226T2 (cg-RX-API-DMAC7.html)
MX (1) MX2020006992A (cg-RX-API-DMAC7.html)
PL (1) PL3735226T3 (cg-RX-API-DMAC7.html)
PT (1) PT3735226T (cg-RX-API-DMAC7.html)
RS (1) RS63687B1 (cg-RX-API-DMAC7.html)
SA (1) SA520412362B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202006313WA (cg-RX-API-DMAC7.html)
SI (1) SI3735226T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202200427T1 (cg-RX-API-DMAC7.html)
TW (2) TWI857944B (cg-RX-API-DMAC7.html)
UA (1) UA126096C2 (cg-RX-API-DMAC7.html)
WO (1) WO2019135954A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7378401B2 (ja) * 2018-01-02 2023-11-13 サイネクシス,インコーポレーテッド リポソームの中にカプセル化されたトリテルペノイド抗真菌薬の注射可能な組成物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5756472A (en) 1996-01-31 1998-05-26 Merck & Co., Inc. Antifungal agent obtained from hormonema
US7718189B2 (en) * 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
NZ589967A (en) * 2004-01-14 2012-07-27 Gilead Sciences Inc Lipid-based dispersions useful for drug delivery
ES2402659T3 (es) 2006-04-03 2013-05-07 Merck Sharp & Dohme Corp. Derivados de enfumafungina como agentes antifúngicos
CA2700530C (en) * 2007-09-28 2014-12-09 Merck Sharp & Dohme Corp. Antifungal agents
US8226965B2 (en) * 2008-04-25 2012-07-24 Nanobio Corporation Methods of treating fungal, yeast and mold infections
JP2011529038A (ja) * 2008-07-23 2011-12-01 ターゲッティド デリバリー テクノロジーズ リミテッド 真菌感染症の処置のための局所抗真菌製剤の投与方法
WO2010019204A1 (en) * 2008-08-12 2010-02-18 Merck Sharp & Dohme Corp. Antifungal agents
PE20120923A1 (es) * 2009-03-30 2012-08-27 Eisai Randd Man Co Ltd Composiciones farmaceuticas comprendiendo liposomas que contiene eribulina o una sal del mismo
PT3247711T (pt) * 2015-01-19 2022-05-16 Scynexis Inc Novos sais e polimorfos de scy-078
JP7378401B2 (ja) * 2018-01-02 2023-11-13 サイネクシス,インコーポレーテッド リポソームの中にカプセル化されたトリテルペノイド抗真菌薬の注射可能な組成物

Also Published As

Publication number Publication date
KR20200105875A (ko) 2020-09-09
BR112020013448A2 (pt) 2020-12-01
US20230277455A1 (en) 2023-09-07
EA202091626A1 (ru) 2020-09-22
JP2025106349A (ja) 2025-07-15
AU2018399599A1 (en) 2020-07-16
UA126096C2 (uk) 2022-08-10
CA3087176A1 (en) 2019-07-11
IL275758B1 (en) 2025-03-01
SMT202200427T1 (it) 2022-11-18
JP2021508728A (ja) 2021-03-11
EP3735226A1 (en) 2020-11-11
EP3735226B1 (en) 2022-08-10
AU2018399599B2 (en) 2022-09-01
JP2024012452A (ja) 2024-01-30
TW202434242A (zh) 2024-09-01
TW201929853A (zh) 2019-08-01
DK3735226T3 (da) 2022-10-24
MA51514A (fr) 2021-04-07
KR102694692B1 (ko) 2024-08-14
CN111655237B (zh) 2023-02-03
WO2019135954A1 (en) 2019-07-11
MD3735226T2 (ro) 2023-03-31
JP7378401B2 (ja) 2023-11-13
EP4137123A1 (en) 2023-02-22
CN111655237A (zh) 2020-09-11
MX2020006992A (es) 2020-09-09
CN115998684A (zh) 2023-04-25
PL3735226T3 (pl) 2022-12-19
TWI857944B (zh) 2024-10-11
RS63687B1 (sr) 2022-11-30
IL318793A (en) 2025-04-01
PT3735226T (pt) 2022-09-20
US20250082574A1 (en) 2025-03-13
HUE060400T2 (hu) 2023-02-28
US20200338002A1 (en) 2020-10-29
LT3735226T (lt) 2022-11-10
HRP20221295T1 (hr) 2022-12-23
TWI862280B (zh) 2024-11-11
SG11202006313WA (en) 2020-07-29
NZ765771A (en) 2024-09-27
SA520412362B1 (ar) 2022-12-15
ES2927051T3 (es) 2022-11-02
IL275758B2 (en) 2025-07-01
IL275758A (en) 2020-08-31

Similar Documents

Publication Publication Date Title
MA54714A (fr) Formulation de nicotine
PL3658140T3 (pl) Połączenia aprocitentanu z dodatkowymi składnikami czynnymi do leczenia opornego nadciśnienia
PL3603620T3 (pl) Kompozycja liposomowa i kompozycja farmaceutyczna
DK3619201T3 (da) Herbicidvirksomme 4-difluormethylbenzoylamider
IL253619A0 (en) Encapsulation of high potency active agents
IL287628A (en) Injectable pharmaceutical compositions and uses thereof
PL3397287T3 (pl) Preparaty o obniżonym poziomie rozkładu polisorbatu
EP3849570A4 (en) Blood plasma-containing compositions
EP3942995A4 (en) SLIT LAMP MICROSCOPE
EP3582748A4 (en) SULPHATE-FREE FORMULATIONS
IL287560A (en) Mrna formulation
DK3649688T3 (da) Dobbeltaktive katodematerialer
DK3411008T3 (da) Sammensætninger omfattende aktive solbeskyttelsesmidler med polyhydroxyfulleren
MA49837A (fr) Compositions pharmaceutiques
IL269305A (en) Cannabinoid formulations and dosage
EP4516342B8 (en) TWO-CHARBORNE COMBINATION SYRINGE
EP4070796A4 (en) AQUEOUS COMPOSITION
LT3582617T (lt) Pesticidinių piridazinpirazolamidų stabili kompozicija
DK3418355T3 (da) Skyllemiddelsaktive sammensætninger
EP3858377A4 (en) INJECTABLE COMPOSITION
IL287416A (en) Topical formulation
EP3949952A4 (en) MEDICAL COMPOSITION
HUE061722T2 (hu) Dezodorkészítmény
DK3324736T3 (da) Hidtil ukendt spot-on-aktivstofformulering
HUE057269T2 (hu) Befecskendezhetõ készítmény